|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Social Anxiety Disorder | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Anxiety Disorders | |||||
| Phobic Disorders | |||||
| 3 | More general conditions related to this trial | ||||
| Mental Disorders | |||||
| 4 | Interventions listed in this trial | ||||
| D-cycloserine | |||||
| Cognitive behavioral therapy (CBT) | |||||
| Placebo | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Cycloserine | |||||
| 6 | More general drug interventions related to this trial | ||||
| Anti-Bacterial Agents | |||||
| Anti-Infective Agents | |||||
| Anti-Infective Agents, Urinary | |||||
| Antibiotics, Antitubercular | |||||
| Antimetabolites | |||||
| Antitubercular Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Renal Agents | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| National Institute of Mental Health (NIMH) | |||||